Detroit, MI 的 卵巢癌 臨床試驗
26 項針對 卵巢癌 的研究正在 Detroit（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
招募中2/3 期
- Henry Ford Hospital, Detroit
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
招募中1/2 期
- Research Site, Detroit
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
招募中觀察性研究
- Henry Ford Health, Detroit
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
招募中1/2 期
- Karmanos Cancer Institute, Detroit
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中2 期
- Site 0101 - Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
招募中1/2 期
- Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
招募中1 期
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
招募中2 期
- Karmanos Cancer Institute - Detroit /ID# 277085, Detroit
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
招募中3 期
- Henry Ford Cancer - Detroit, Detroit
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
招募中2 期
- Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Karmanos Cancer Institiute, Detroit
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
招募中3 期
- Karmanos Cancer Institute, Detroit
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
招募中1 期
- Karmanos Cancer Institute, Detroit
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
招募中1 期
- Karmanos Cancer Center, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- Henry Ford Health Saint John Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Karmanos Cancer Institute, Detroit
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
招募中1 期
- Karmanos Cancer Institute, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Henry Ford Health Hospital, Detroit
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
招募中2 期
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
招募中2 期
- Karmanos Cancer Institute - Detroit /ID# 272112, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
招募中1/2 期
- Karmanos Cancer Institute, Detroit
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
招募中1 期
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
招募中1/2 期
- Karmanos Cancer Institute, Detroit
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
招募中1 期
- Karmanos Cancer Institute, Detroit
其他城市的 卵巢癌 試驗
- Houston, TX89 項研究
- New York City, NY69 項研究
- Boston, MA61 項研究
- Los Angeles, CA50 項研究
- Nashville, TN49 項研究
- Arlington, VA46 項研究
- Philadelphia, PA44 項研究
- Columbus, OH39 項研究
- St. Louis, MO38 項研究
- Chicago, IL36 項研究
- San Antonio, TX31 項研究
- Cleveland, OH30 項研究
Detroit 的其他研究
- 非小細胞肺癌44 項研究
- 乳癌33 項研究
- 癌症（所有類型）29 項研究
- 大腸直腸癌26 項研究
- 轉移性癌症24 項研究
- 前列腺癌22 項研究
- 子宮內膜癌21 項研究
- 肺癌20 項研究
- 多發性骨髓瘤19 項研究
- 胃癌16 項研究
- 頭頸部鱗狀細胞癌15 項研究
- 急性髓系白血病14 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。